Recursion Pharmaceuticals

Najat Khan serves as CEO, while Chris Gibson — the co-founder who originated the cellular imaging approach — remains chairman. The executive team oversees distinct research, clinical, and technology functions that feed the Recursion OS platform. The firm lists ten board members with deep biotech and AI expertise.

Recursion replaces hypothesis-driven discovery with a high-throughput, image-based phenomics engine. Computer vision extracts features from millions of cell experiments, and machine-learning models map those features to disease biology. This closed loop permits rapid target identification, lead optimization, and safety screening.

The pipeline includes REC-3565, a MALT1 inhibitor in Phase 1 for B-cell lymphomas, and studies targeting solid tumors such as ELUCIDATE and DAHLIA. The company focuses on first-in-class and best-in-class therapies for aggressive cancers and rare diseases with high unmet need.

Yes. Recursion pursues pharmaceutical partnerships, technology collaborations (notably with NVIDIA, which co-built the BioHive-2 supercomputer), and data partnerships that augment its proprietary datasets. These alliances help accelerate discovery and extend the platform's reach.

As disclosed by the firm, the dataset exceeds 50 petabytes across phenomics, transcriptomics, proteomics, ADME, and de-identified patient records. Automated labs in Salt Lake City continuously generate new data, which feeds back into the Recursion OS models.